BioCryst Pharmaceuticals CEO Charlie Gayer Plans Expansion into Rare Disease Drug Development Following Profitability
BioCryst Pharmaceuticals is leveraging its recent profitability to expand its portfolio in the rare disease sector by acquiring new treatments, aiming to fill a gap left by larger pharmaceutical companies.